Potential Treatment for Early Polymyalgia Rheumatica (PMR)
Trial Summary
What is the purpose of this trial?
This Phase 4 study tests whether sarilumab (Kevzara) can help adults with newly diagnosed or early relapsing polymyalgia rheumatica (PMR). Researchers aim to assess whether sarilumab can help control PMR symptoms while reducing reliance on long-term steroid use.
Why do researchers think this study treatment might be promising?
PMR is currently treated with corticosteroids like prednisone, which can cause significant side effects when used for long periods. Sarilumab works by targetting the inflammation behind PMR. By targeting inflammation at its source, the study drug may help patients achieve sustained relief while reducing the amount of steroid they need.
Timeline
Screening
Participants are evaluated to confirm eligibility
Treatment Period
Participants receive sarilumab or placebo by injection every 2 weeks
Follow-up
Participants are monitored after completing treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.